For the third quarter of the fiscal year ending August 2026, revenue was approximately JPY 2.53 billion, a 2.2% increase YoY. Strong performance in pharmaceutical and healthcare businesses led to sustained revenue growth, while total net income was JPY 117 million, a decrease of 82.6% YoY.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2927","jir_company_name":"AFC-Hd Amus Life Sciences Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-07-15","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/2927-20260715-01.pdf","jir_short_summary":"For the third quarter of the fiscal year ending August 2026, revenue was approximately JPY 2.53 billion, a 2.2% increase YoY. Strong performance in pharmaceutical and healthcare businesses led to sustained revenue growth, while total net income was JPY 117 million, a decrease of 82.6% YoY.","jir_summary":"### Performance Overview\nIn the third quarter of the fiscal year ending August 2026, the Company achieved revenue of approximately JPY 2.53 billion (up 2.2% YoY), mainly driven by steady growth in pharmaceutical and healthcare segments. However, net income declined significantly to approximately JPY 117 million, a decrease of 82.6% compared to the same period last year. Segments such as pharmaceuticals and healthcare continued to perform well, with real estate, construction, and restaurant businesses also expanding. The Company will continue to focus on strong pharmaceutical performance and new business development to achieve its full-year forecast.\n\n### Outlook and Impact on Investors\nThe Company projects full-year revenue of approximately JPY 3,413 million, representing a 4.5% increase YoY. The strategy involves leveraging the steady pharmaceutical business and expanding the tourism and real estate segments to enhance profit margins. The company plans to maintain dividend payments as part of shareholder returns, while working toward sustainable growth and stable earnings. For investors, the diversification into new businesses and the focus on pharmaceuticals are attractive points.","jir_financial_highlights":"Revenue: JPY 25,279 million (YoY +2.2%)\nNet income attributable to owners of the parent (quarterly): JPY 1,166 million (YoY -17.4%)\nFull-year revenue forecast: JPY 34,137 million (YoY +4.5%)","jir_category":"","jir_hashtags":"#AFC-HdAmusLifeSciences, #FinancialResults, #JapanStocks","jir_key_figures":"Revenue: JPY 25,279 million (YoY +2.2%)\nNet income attributable to owners of the parent (quarterly): JPY 1,166 million (YoY -17.4%)\nFull-year revenue forecast: JPY 34,137 million (YoY +4.5%)","jir_meta_title":"\u3010AFC-Hd Amus Life Sciences\u3011Q3 2026 Financial Results \uff5c Revenue approximately JPY 2.53 billion (YoY +2.2%)","jir_meta_description":"Overview of AFC-Hd Amus Life Sciences' Q3 2026 financial results ending August 2026. Revenue increased to approximately JPY 2.53 billion with steady growth in pharmaceuticals and healthcare sectors. Outlook also discussed.","jir_og_title":"\u3010AFC-Hd Amus Life Sciences\u3011Q3 2026 Financial Results \uff5c Revenue approximately JPY 2.53 billion","jir_og_description":"Summary of AFC-Hd Amus Life Sciences' Q3 2026 financial results. Focus on revenue growth and business expansion. Provides information useful for investment decisions.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":58627,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-81487","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n